Halozyme Corp (HALO): Rasio rega marang prakiraan pendapatan

Simbol resmi perusahaan Halozyme (HALO)

Halozyme Therapeutics (HALO) is a reputable developer of drug delivery systems with an impeccable scientific standing. The forward P/S metric illustrates the business valuation trend, where the 2.60 mark characterizes this parameter. However, revenues rely on a narrow circle of partners, creating a risk of declining royalties. Meanwhile, unique patents ensure exceptional pricing power by converting injections into a subcutaneous format.

HALO Halozyme Therapeutics, Inc.: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 04.07.2022 - 17.11.2026

HALO (halozyme.com): rincian analitis lan laporan miturut indikator

Analisis kabeh metrik perusahaan:halozyme.com HALO
Produk sing diprodhuksi Halozyme Therapeutics

Halozyme Therapeutics (HALO) maintains a dominant position by monetizing unique drug delivery methods through a system of long-term royalties. The forward P/S ratio assesses the market value of every dollar of projected revenue, allowing investors to determine the extent of overpayment for expected cash flows. This chart's price action reveals that the asset is overheated, signaling a risk of correction if market expectations outpace the actual growth rate of licensing fees.

Analisis pesaing

Multiplikator Forward P/S ONC (BeiGene Oncology)|Revolution Medicines (RVMD) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ascentage.com - Multiplikator Forward P/S|Rega forward marang dodolan CGON (cgoncology.com)|URGN: Multiplikator Forward P/S|Bicara Therapeutics Inc (BCAX) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan personalis.com|Multiplikator forward rega marang pendapatan Erasca Corp (ERAS)|Multiplikator forward rega marang pendapatan DCTH (Delcath)|Rasio kapitalisasi marang dodolan sing dikarepake Y-mAbs Therapeutics, Inc.|Multiplikator Forward P/S AURA (Aura Biosciences Inc)|Rega forward marang dodolan CADL|ARAY: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan CTOR|Rasio rega marang prakiraan pendapatan TuHURA Biosciences Inc.|TARA: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Fate Therapeutics (FATE)|Rasio kapitalisasi marang dodolan sing dikarepake Aadi Bioscience|Rasio rega marang prakiraan pendapatan TScan Therapeutics Inc TCRX|CSBR: Kapitalisasi marang prakiraan pendapatan|XBIT: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CVM (cel-sci.com)|OSTX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ANL (Adlai Nortye)|Rasio rega marang prakiraan pendapatan Veru Pharma (VERU)|Multiplikator Forward P/S Tempest Tx (TPST)|Rasio rega marang prakiraan pendapatan xiliotx.com XLO|Enochian BioSciences - Rasio rega marang prakiraan pendapatan|Mural Oncology - Multiplikator Forward P/S|KAPA - Multiplikator Forward P/S|OnKure Therapeutics Inc (OKUR) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan CytoMed|Rasio rega marang prakiraan pendapatan curis.com|Multiplikator forward rega marang pendapatan Apollomics, Inc. (APLM)|Multiplikator Forward P/S THAR|Advanced Biomed Corp - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Genprex GNPX|Rasio kapitalisasi marang dodolan sing dikarepake Calidi Bio (CLDI)|sunshinebiopharma.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep xeneticbio.com|salariuspharma.com (SLRX) - Rasio rega marang prakiraan pendapatan|Purple Biotech Ltd. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan AON|Multiplikator Forward P/S BeiGene Ltd.|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|Multiplikator forward rega marang pendapatan Elevation Oncology, Inc. ELEV|Multiplikator Forward P/S ICAD (iCAD Inc.)|IKNA - Multiplikator forward rega marang pendapatan|NTBL: Multiplikator forward rega marang pendapatan|viracta.com (VIRX) - Multiplikator forward rega marang pendapatan|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Corp (NAYA) - Multiplikator Forward P/S|AAPGV (Ascentage) - Multiplikator Forward P/S